NeoPharm CO. LTD
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELE… Read more
NeoPharm CO. LTD (092730) - Total Assets
Latest total assets as of September 2025: ₩207.38 Billion KRW
Based on the latest financial reports, NeoPharm CO. LTD (092730) holds total assets worth ₩207.38 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NeoPharm CO. LTD - Total Assets Trend (2012–2024)
This chart illustrates how NeoPharm CO. LTD’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NeoPharm CO. LTD - Asset Composition Analysis
Current Asset Composition (December 2024)
NeoPharm CO. LTD's total assets of ₩207.38 Billion consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.5% |
| Accounts Receivable | ₩10.85 Billion | 5.6% |
| Inventory | ₩12.68 Billion | 6.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.95 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how NeoPharm CO. LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NeoPharm CO. LTD's current assets represent 79.5% of total assets in 2024, an increase from 46.8% in 2012.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2024, up from 4.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 14.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 6.6% of total assets.
NeoPharm CO. LTD Competitors by Total Assets
Key competitors of NeoPharm CO. LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Globon Co. Ltd
KQ:019660
|
Korea | ₩20.12 Billion |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
Korea | ₩165.86 Billion |
|
Gentrogroup Co. Ltd.
KQ:083660
|
Korea | ₩34.38 Billion |
|
Auxilia SA
WAR:AUX
|
Poland | zł45.57 Million |
|
Nextbike Polska SA
WAR:NXB
|
Poland | zł60.52 Million |
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Kukyoung G&M
KO:006050
|
Korea | ₩71.75 Billion |
NeoPharm CO. LTD - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - NeoPharm CO. LTD generates 0.62x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, NeoPharm CO. LTD generates $ 11.99 in net profit.
NeoPharm CO. LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.36 | 10.99 | 7.63 |
| Quick Ratio | 8.55 | 9.86 | 7.09 |
| Cash Ratio | 0.00 | 0.95 | 0.00 |
| Working Capital | ₩149.57 Billion | ₩ 130.89 Billion | ₩ 98.67 Billion |
NeoPharm CO. LTD - Advanced Valuation Insights
This section examines the relationship between NeoPharm CO. LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.69 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.4% |
| Total Assets | ₩192.44 Billion |
| Market Capitalization | $55.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values NeoPharm CO. LTD's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: NeoPharm CO. LTD's assets grew by 8.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for NeoPharm CO. LTD (2012–2024)
The table below shows the annual total assets of NeoPharm CO. LTD from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩192.44 Billion | +8.44% |
| 2023-12-31 | ₩177.46 Billion | +14.23% |
| 2022-12-31 | ₩155.35 Billion | +8.33% |
| 2021-12-31 | ₩143.41 Billion | +7.84% |
| 2020-12-31 | ₩132.98 Billion | +8.34% |
| 2019-12-31 | ₩122.74 Billion | +68.30% |
| 2018-12-31 | ₩72.93 Billion | +28.63% |
| 2017-12-31 | ₩56.69 Billion | +21.90% |
| 2016-12-31 | ₩46.51 Billion | +15.09% |
| 2015-12-31 | ₩40.41 Billion | +18.36% |
| 2012-12-31 | ₩34.14 Billion | -- |